Harvard Bioscience (HBIO) Gross Margin (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Gross Margin data on file, last reported at 58.99% in Q1 2026.

• On a quarterly basis, Gross Margin rose 304.0% year-over-year to 58.99% in Q1 2026; TTM through Mar 2026 was 58.42%, a 133.0% increase from a year earlier, with the FY2025 full-year figure at 57.67%, down 51.0% from the prior year.
• Gross Margin for Q1 2026 stood at 58.99%, down from 59.71% in the prior quarter.
• Over the last five years, Gross Margin for HBIO reached as high as 61.2% in Q1 2023 and fell as low as 45.21% in Q3 2022.
• Historically, Gross Margin has averaged 57.14% across 5 years, with a median of 57.97% in 2023.
• Across the five-year window, Gross Margin sank 977 bps in 2022 and jumped 1285 bps in 2023, its largest moves.
• Year by year, Gross Margin stood at 55.7% in 2022, then grew by 4 bps to 57.99% in 2023, then retreated by 2 bps to 57.06% in 2024, then advanced by 5 bps to 59.71% in 2025, then retreated by 1 bps to 58.99% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 58.99% in Q1 2026, 59.71% in Q4 2025, and 58.38% in Q3 2025.